


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
(Modified)**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

1 of 3

**Complete if Known**

Application Number	10/520/712
Filing Date	July 8, 2003
First Named Inventor	Colland, et al.
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	Docket 186208 US 455569-14

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-2003235910	12-25-2003	Monia et al.	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO 0050588	08-31-2000	Incyte Pharma, Inc.		
	B2	WO 0070076	11-23-2000	Human Genome Sciences, Inc.		
	B3	WO 0073801	12-07-2000	Ludwig Inst Cancer Res		
	B4	WO 0198350	12-27-2001	Chiron, Inc.		
	B5	WO 0200939	01-03-2002	Diaexus, Inc.		
	B6	WO 02051438	07-04-2002	Max Planck Gesellschaft		
	B7	WO 02084294	10-24-2002	Axxima Pharamaceuticals AG		
	B8	WO 0229103	04-11-2002	Gene Logic Inc.		
	B9	WO 03000928	01-03-2003	Mortensen Shila		
	B10	WO 9528484	10-26-1995	Amgen, Inc.		
	B11	WO 9948921	09-30-1999	Stanford		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
--------------------	-----------------------	---	----------------

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/520/712
				Filing Date	July 8, 2003
				First Named Inventor	Colland, et al.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	3	Attorney Docket Number	Docket 186208 US 455569-14

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	† <sup>6</sup>	
	C1	Bohm, "The computer program Ludi: A new method for the de novo design of enzyme inhibitors", <i>J. Comp. Aided Molec. Design</i> , 6:61-78		
	C2	Chen & McCormick, "Selective Targeting to the hyperactive $\beta$ -catenin/TCF pathway in colon cancer cells", <i>Cancer Res.</i> 2001 61:4445		
	C3	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interferences in cultured mammalian cells", <i>Nature</i> 411: 494-498, 2001		
	C4	Florian et al., "Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue", <i>Free Radical Research</i> , December 2001, vol. 35, no. 6, December 2001, pps. 655-663		
	C5	Fuerer & Iggo, "Adenovirus with TCF-binding sites in multiple early promoters show enhanced selectivity for tumor cells with constitutive activation of the Wnt signaling pathway", <i>Gene Ther.</i> 2002 9:270		
	C6	Harada et al., "Introduction of antisense CD445 CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells" <i>International Journal of Cancer</i> , January 1, 2001, vol. 91, no. 1, pps. 67-75		
	C7	Herzig et al., "Recent advances in cancer research: mouse models of tumorigenesis", <i>BBA-Reviews on Cancer, Elsevier Science BV, Amsterdam, NL</i> , vol. 1602, no. 2, 21 June 2002, pps. 97-113		
	C8	Holder et al., "Eph receptors and ephrins: Effectors of morphogenesis" <i>Development</i> vol. 126, no. 10, May 1999, pps. 2033-2044		
	C9	Jones et al., "Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation" (1995) <i>J. Mol. Biol.</i> , 245: 43-53		
	C10	Kataoka et al., "Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer" <i>Journal of Cancer Research and Clinical Oncology</i> , vol. 128, no. 7, July 2002, pps. 343-348		
	C11	Kelner et al., "Structural organization of the human gastrointestinal glutathione peroxidase (GPX2) promoter and 3'-nontranscribed region: transcriptional response to exogenous redox agents", <i>Gene, Elsevier Biomedical Press</i> , vol. 248, no. 1-2, May 2000		
	C12	Kiyakawa et al., "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors" <i>Cancer Research</i> ISSN 008-5472, vl. 54, no. 14, 1994, pps. 3645-3650		
	C13	Lipinski et al., "High level $\beta$ -catenin/TCF dependent transgene expression in secondary colorectal cancer tissue" <i>Mol. Ther.</i> 2001 4:365		
	C14	Mariadason et al. "Down-regulation of beta catenin TCF signaling is linked to colonic epithelial cell differentiation" <i>Cancer Research</i> 15 April 2001, vol. 61, no. 8, pps. 3465-3471		
	C15	Moerk et al., "Inverse MRNA Expression of the Selenocysteine-containing proteins GI-GPX and SEP in colorectal adenomas compared with adjacent normal mucosa" <i>Nutrition and Cancer</i> , vol. 37, no. 1, 2000, pps. 1089-116		
	C16	Naishiro et al., "Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation", <i>Cancer Research</i> , 15 March 2001, vol. 61, no. 6, pps. 2751-2758		
	C17	Nicholls et al., "Protein Folding and Association: Insights from the Interfacial and Thermodynamic Properties of Hydrocarbons", <i>Structure, Function and Genetics</i> , (1991) 11:281-283		
	C18	Oving et al., "Molecular causes of colon cancer" <i>European Journal of Clinical Investigation England</i> , vol. 32, no. 6, June 2002, pps. 448-457		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/520/712
				Filing Date	July 8, 2003
				First Named Inventor	Colland, et al.
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	Docket 186208 US 455569-14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C19	Schwartzberg, "Clinical experience with ederecolomaoab: a monoclonal antibody therapy for colorectal carcinoma", <i>Crit. Rev. Oncol. Hemtol.</i> , 40: 17-24, 2001	
	C20	Su et al., "Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene", <i>Science</i> 256: 668-670	
	C21	Tetsu et al., "β-catenin regulates expression of cyclin D1 in colon carcinoma cells", <i>Nature</i> 398: 422-426	
	C22	Vogt et al., "Eph-receptor tyrosine kinase profiles malignant melanomas at a glance: cDNA miniarray discloses expression profiles indicative for redundant autocrine loops", <i>Proceedings of American Association for Cancer Research</i> , No. 41, March 2000, page 788	
	C23	Wielenga et al., "Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.", <i>American Journal of Pathology</i> , vol. 154, no. 2, February 1999, pps. 515-523	
	C24	Yamato et al., "Overexpression of Orphan G-Protein-Coupled Receptor, Gpr49, in Human Hepatocellular Carcinomas with β-Catenin Mutations" <i>Hepatology</i> , 2003, 37: 528-533	
	C25	Zou et al., "An Eph Receptor regulates integrin activity through R-Ras" <i>Proceedings of the National Academy of Sciences of the United States</i> , 23 November 1999, pps. 13813-13818	

Examiner Signature	/Laura B. Goddard/	Date Considered	10/01/2008
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./